Okey Stephanie sold (to issuer) $1.0M of CRNX
Okey Stephanie sold (to issuer) 12,325 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.05M total) across 2 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
The complete divestiture may be viewed as a slight bearish cue, but the transaction size is modest.
Market read
Routine insider sale with limited immediate market impact.
What to watch
Director may have tax or personal reasons unrelated to company outlook.
Background
Form 4 filings disclose insider transactions; this one shows a director exiting the company entirely.
Ticker impact
Director Okey Stephanie sold all 12,325 shares for $1.05M via a Form 4 filing.
Minor downward pressure in the short term.
Sale size is modest relative to market cap; impact likely limited.
Market effects
No broader sector impact; typical insider transaction.
Limited to US biotech sector sentiment.
Minimal global relevance.
Counterpoint
Sale could be routine liquidity need, not a negative signal.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biopharma listed on NASDAQ under ticker CRNX.
- InsiderOkey Stephanie
Director of Crinetics who sold all holdings.
